GLP-1 RAs: Which Ones for Which Patients?

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now firmly established as guideline-recommended antiglycemic agents of choice in patients with type 2 diabetes, especially when comorbid disease is evident or when the patient is at high risk for such conditions. Join Davida Kruger, NP and Anne Peters, MD for a lively discussion on the use of GLP-1 RAs in clinical practice, including how to use shared decision-making to choose an ideal agent based on patient, disease, and GLP-1 RA characteristics. The unique effects of GLP-1 RAs on cardiovascular disease and weight mitigation are also discussed in the context of patient selection and management.

This episode is available for CE/CME credit.